Biogen: Statement on Alzheimer’s & Dementia® Journal publication on association between reduced beta-amyloid and slowing cognitive and functional decline in Alzheimer’s disease


Today, Alzheimer’s and dementia: the journal of the Alzheimer’s Association published an updated meta-analysis demonstrating a likely causal association between clearance of beta-amyloid plaques in the brain and slower cognitive and functional decline in Alzheimer’s disease. These results suggest that beta-amyloid plaque remains a viable biological target for the prevention and treatment of Alzheimer’s disease.

The findings are based on updates to a meta-analysis published in the British Medical Journal (BMJ) on February 25, 2021, which concluded that reducing amyloid levels alone was unlikely to significantly slow the cognitive decline during the follow-up period of most typical trials. The original authors created a web interface with an interactive version of their analysis to encourage updates and recalculations from other researchers. The updated meta-analysis released today used the same methodology as the original with the addition of two new clinical trials in the analysis.

“The totality of the analysis updates led to the discovery of a causal association between clearance of beta-amyloid plaques in the brain and slower cognitive decline across all parameters assessed, an intriguing contrast to the original results,” said study co-author Robert Platt, Ph.D., Professor and Albert Boehringer Chair, McGill University, Departments of Epidemiology, Biostatistics, Occupational Health and Pediatrics . “We hope this work can continue to evolve and inform clinical development and advance the field of Alzheimer’s disease research as a whole.”

Clearance of beta-amyloid was measured by positron emission tomography (PET) with normalized uptake value ratio (PET-SUVR). The effect of beta-amyloid removal on cognitive and functional decline was statistically significant for all endpoints assessed in the original analysis: clinical assessment of dementia – sum of boxes (CDR-SB), Alzheimer’s Disease Rating Scale – Cognitive Subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE).

The full publication entitled “Effect of reducing brain amyloid levels on changing cognitive and functional decline in randomized clinical trials: a meta-analysis of instrumental variables” is available on the website of the Journal of Alzheimer’s Disease and Dementia.


Biogene Inc. published this content on August 31, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on Aug 31, 2022 11:40:06 AM UTC.


Comments are closed.